BioAge Labs Stifel 2026 Healthcare Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Are you on? Yes. Okay. Good afternoon, everyone, and welcome to the BioAge Labs presentation. BioAge, as you know, is targeting NLRP3 to address diseases of aging and inflammation. With us today is BJ Sullivan, Chief Strategy Officer of BioAge. Why don't you come on and give us the presentation, and we'll go into Q&A.
Sounds great, and thank you for having us today. We appreciate it. Thanks to all of you who are attending in person and virtually. I am going to start off and give you a brief corporate presentation and an overview of our programs, and then we can go into Q&A. BioAge is a platform company. We are essentially harnessing the biology of human aging and using that as a lens for target discovery and targeting pathways associated with healthy aging. Our lead program is BGE-102. It's a potential best-in-class oral NLRP3 inflammasome inhibitor. We released our phase I data earlier this year, showing what we believe to be a best-in-class profile, with essentially 98% trough inhibition of IL-1β and 86% reduction of hsCRP in obese and inflamed individuals.
All of that in a convenient once-daily dosing paradigm, with placebo-like tolerability and really excellent tissue distribution, which enables us to go after diseases driven by inflammation, not only in the periphery, but also in protected compartments like the retina. With this program, we have two ongoing phase II trials. One is QUELL-CV, which is a peripheral dose-ranging study where we're looking at three doses of BGE-102 and trying to understand the relationship between those exposure as well, and a rich set of inflammatory and metabolic biomarkers, as well as MRI imaging of the liver. That's reading out at the end of this year. We also have the ongoing QUELL-DME trial, which is enrolling and is targeting data by the end of next year.
There, we're looking at NLRP3 both as a monotherapy and as a combination with anti-VEGF to see if we can improve visual acuity in these patients. We see this really as a beachhead into a broader ophthalmology strategy, which takes advantage of the fact that we really have exceptional tissue distribution, which we showed in the clinic, getting very nice levels in the CSF. Across non-clinical species, including primates, we see very high free levels in the retina. We're really leaning into this differentiated profile of our molecule. I would also say that we're planning to announce an additional indication for NLRP3 and plan to announce that once those plans are fully solidified. That's also on the horizon for that program. We're also very excited to be back in the clinic soon with APJ.
This is a target that, in our platform, is among the most highly associated with both longevity and preservation of physical function. This is a target when you combine APJ agonism with an incretin or actually any mechanism that causes weight loss due to appetite suppression. We've shown the ability to double weight loss and restore body composition back to that of lean control animals. Actually, with a first-generation compound, we were able to show in older participants at bed rest essentially full preservation of muscle size, muscle quality, and essentially muscle protein synthesis. We have two next-generation programs we're working on, an oral and a parenteral, and we're targeting IND submission by the end of this year, and that's on track, at which point we'll essentially debut the program as well as our clinical development plans.
We're very excited to be back in the clinic with APJ very shortly. I'm going to give you a brief overview of the BGE-102 program. NLRP3 is essentially an inflammasome in the body that's responsible for essentially translating sterile inflammatory signals into both cytokine production and release, IL-1β and IL-18, as well as mediating the inflammatory cell death process called pyroptosis. There are other inflammasomes in the body, but NLRP3 is really the key mediator of sterile inflammation. By that, I mean inflammatory signals that are not associated with an infection or a pathogen. This could be metabolic stress, nutrient excess, a lot of the things we associate with creating this sort of chronic simmering inflammation. Those are mediated by NLRP3. In our cohort, we see that NLRP3 activity is highly associated with mortality in humans.
BGE-102 is our lead program, and we'll get into this in more detail, but we think it has best-in-class potency with an IC90 of 1.6 nanomolar. In the clinic, we're seeing 98% suppression of IL-1β trough at the 120 milligram dose. We're getting 24 hours of essentially complete target inhibition. We feel that we're able to really inhibit this target almost completely with essentially placebo-like tolerability and a high degree of CNS penetration. We did lumbars in our phase I and showed a Kp,uu,CSF of 0.7, which we think is best in class.
I would also note here that we'll get into a little bit of the unique binding site, which we've characterized, and the IPs around that and around this molecule are out to 2045, with claims not only for the specific structures, but also broadly covering ligands that interact with this binding site. NLRP3 has been a target of interest for drug development for 20 years. The original compound that Pfizer took into the clinic was MCC950. This targeted the ATPase pocket on the molecule. To our knowledge, all of the other programs in development are essentially derivations of that structure or novel chemotypes targeting that binding site. We did a sort of a de novo approach. We did a DEL screen. We blocked that binding site, intentionally looking for novel binding sites.
We were able to characterize this with a collaboration with Matthias Geyer at the University of Bonn, and we've published on this extensively. This binding site is distinct, and what it enables is the ability to inhibit the inflammasome, both in its active and inactive form. What we see is that we're really able to completely inhibit the target. The inflammasome and NLRP3, it has a monomeric form, and then it assembles into a decamer in this really big scaffolded inflammasome assembly that is required to process the cytokines and initiate pyroptosis. Once that complex assembles, it appears that the original binding site is blocked. We think that this binding site may, in part, explain why we're able to achieve the depth of target inhibition that we've shown in the clinic.
To go over our phase I results, these are the results that we shared in April of this year. This included essentially a standard SAD/MAD with healthy volunteers, and we also included two cohorts of obese and inflamed individuals. Essentially, this was informed by the Ventyx trial, which had read out and essentially showed that in patients, some similar patients, you basically achieve maximum biomarker reductions within a couple weeks. We think the goal was to show, okay, what is the depth of the biomarker reductions that you're able to achieve, with the expectation that we'll be able to sustain those over chronic dosing? The highlights here are basically, safety tolerability was really placebo-like, excellent, and across the phase I. Nice dose proportionality with clearly supporting once-daily dosing.
From a biomarker and pharmacodynamic perspective, again, we were able to achieve essentially 24 hours of complete target inhibition. In both of the doses we tested in these obese and inflamed individuals, we were able to achieve an 86% reduction in CRP. I'm just going to walk you through some of the key findings here. This is the CSF PK from lumbar punctures in healthy individuals, and you can see that this is basically a steady state level at the 60 milligram QD dose. We were able to achieve essentially IC90 coverage in the CSF, which rose to about 3X the IC90 at the 120 milligram dose. Very nice tissue distribution into the CSF. This is essentially showing the magnitude of target inhibition.
This is an ex vivo stimulation of blood from these patients, healthy volunteers, 60 and 120 milligrams QD, and we're basically able to show up to 98% suppression of the target. This basically tells you the same thing, but I think it illustrates it in a very visual way. You can just see here, this is the 120 milligram dose group at day one, day eight, and day 14. What we're able to show is that by day eight, you're basically getting 24 hours of complete target inhibition, right? We're really knocking the target down for that full 24-hour period. This is one slide just summarizing the data from the obese inflamed MAD cohorts. You can see here in the 60 milligram and the 120 milligram MAD cohorts, we were able to achieve an 86% reduction in CRP.
As we go into the QUELL-CV trial, the dose-ranging trial that is reading out at the end of this year, one of the goals of that is to really understand what is the dose response relationship between BGE-102 and then these metabolic and inflammatory biomarkers. You may not need to have 98% trough inhibition of IL-1β to have maximal effect on some of these downstream markers. That is one of the key goals of the ongoing study. To briefly touch on therapeutic areas, we think we have the ability to address inflammation very broadly across compartments. Not only do we think we have potential best-in-class performances for an NLRP3 inhibitor full stop, but because we have demonstrated very high penetration into the CSF, we think obviously that that compartment is highly addressable.
Across non-clinical species we have looked at, including primates, we see excellent exposure in the retina. That is obviously one of the anchor therapeutic areas for us as well. We think we are able to address inflammation broadly regardless of the compartment. This is the design of the QUELL-CV trial, which is currently ongoing and going to read out at the end of the year. It is dose-ranging. We are looking at three doses of BGE-102 and placebo, so we are looking at 30, 60, and 90 milligrams QD. 90 milligrams essentially is the PK equivalent at steady state to the 120 milligram dose we tested in phase I, where we expect similar 98% trough suppression of IL-1β.
We expect 60 and 30 milligrams are going to give us lower levels of IL-1β suppression, and so we are trying to interrogate really, again, the dose response and relationship to downstream markers like CRP, which is the primary endpoint, as well as a variety of other inflammatory and metabolic markers that we are looking at. We will also be looking at MRI imaging of the liver, so we will look at liver fat as well as liver inflammation, which Ventyx showed a benefit in their three-month trial. We will be able to look at a much richer set of these markers and looking at markers that take longer to change than would have been feasible to measure in the context of the phase I. This broadly supports cardiometabolic indications.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
1 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
